Earnings

Gross margin was 70.9%, against 82.2% a year earlier, which included the deferred China revenue; the prior-year figure was 75.5% without it.Operating Incomewas USD 5.5 million and adjusted EBITDA was USD 14.4 million, or USD 0.28 per diluted share. For the first nine months, …

An at-the-market program lets a company sell new shares into the open market over time, which raises cash but increases the share count and can pressure the price. A standby equity purchase agreement is a similarFacilitywith a single investor, so replacing it signals a …

The segment detail explains why investors are focused on the divestiture. Cancer Care Continuum revenue was USD 123.9 million, up 1%, on 98,000 tests, up 4%. Mental Health, which includes GeneSight, delivered USD 39.5 million, up 2%, on 141,000 tests. Prenatal Health fell 12% …

Chief Financial Officer Patrick Pohlen said third-quarter revenue was affected by execution problems in the go-to-market organization and that guidance was updated to reflect a realignment of the sales team. That matters because theBusinesssells connected-TVAdvertisingthrough a self-serve platform, so revenue follows how many marketers …

Customer activity was strong. Active buyers hit a record 1.82 million, up 16%, and orders grew 17% to 1.89 million. Chief Executive James Reinhart, a co-founder, said in the release: "We're proud to report a record quarter for active buyers, orders and items sold." …

Growth came at a cost. Selling, general and administrative expenses climbed to USD 99.6 million from USD 62.4 million, which is roughly a 60% rise by simple arithmetic on two published numbers, whileResearch and Developmentwas USD 22.4 million against USD 19.6 million. Cash, restricted …

Chairman and Chief Executive Zvi Alon said revenue was within guidance and that adjusted EBITDA exceeded the high end of the range. Operating expenses were USD 11.2 million, down 10.0%. For nine months, revenue was USD 74.6 million against USD 73.5 million, and GAAP …